U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07604571) titled 'Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer' on May 18.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Study Start Date: June 12
Study Type: INTERVENTIONAL
Condition:
Advanced HR+/HER2- Breast Cancer
Intervention:
DRUG: IEV407
Oral administration
DRUG: Fulvestrant
Intramuscular i...